New Delhi, January 16
Amid the rollout of the world's largest Covid-19 vaccination programme by Prime Minister Narendra Modi, here are a few things that you need to know about the two vaccines—
URL copied
Covaxin and Covishield: All you need to know about India s COVID-19 vaccines
Amid the rollout of the world s largest Covid-19 vaccination programme by Prime Minister Narendra Modi, here are a few things that you need to know about the two vaccines Covaxin and Covishield selected by the Drugs Controller General of India (DCGI).
Covaxin and Covishield: Here s all you need to knowÂ
So far, the government has procured 1.1 crore Covishield and 55 lakh Covaxin vaccines at a cost of Rs 200 and Rs 206 per dose, respectively.
Covaxin, developed by Hyderabad-based Bharat Biotech, is the country s first indigenous vaccine against the virus and it has been developed with the help of the Indian Council of Medical Research (ICMR) and National Institute of Virology.
As the country started the Covid-19 vaccine rollout on Saturday, Karnataka administered its first dose of vaccine to Bengaluru s K C. General Hospital s D group employee, Chandrashekar, while Mallasandra PHC doctor, Komal was the second .
Will Prefer Covishield Over Covaxin : Delhi Hospital Doctors Concerned Will Prefer Covishield Over Covaxin : Delhi Hospital Doctors Concerned The resident doctors must believe in the system, Dr VK Paul of the NITI Aayog said, reiterating the safety of Covaxin.
We will prefer Covishield over Covaxin, the resident doctors are saying.
Highlights
They said Covishield completed all three stages of trials as required
Covaxin is still only undergoing stage 3 trials, they added
New Delhi:
Resident doctors at one of Delhi s biggest healthcare hubs, the Ram Manohar Lohia Hospital, on Saturday demanded they be administered Covishield vaccine and not Covaxin since the former has completed all three stages of trials as required under protocol. The second one, produced by Hyderabad-based Bharat Biotech, is still only undergoing stage-III trials. The central government has, however, sought to underplay such apprehensions saying a lot of work had gone into the development of both p